Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

i.d.b. radiopharmacy b.v. - lutetium (177lu) chloride - radionuclide imaging - therapeutic radiopharmaceuticals - lumark is a radiopharmaceutical precursor. it is not intended for direct use in patients. this medicinal must be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuclide imaging - therapeutic radiopharmaceuticals - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

ge healthcare limited - indium (111 in) chloride solution - radio-pharm precursor - 370 mbq/ml

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

ge healthcare limited - indium oxine (in-111) - radio-pharm precursor

Israel - Inggeris - Ministry of Health

promedico ltd - patent blue v sodium - solution for injection - patent blue v sodium 25 mg/ml - other diagnostic agents - marking lymph vessels and arterial regions.marking sentinel nodes before biopsy in patients with operable breast cancer.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - tisagenlecleucel -

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - inotuzumab ozogamicin, quantity: 1 mg - injection, powder for - excipient ingredients: sucrose; trometamol; sodium chloride; polysorbate 80 - besponsa is indicated for the treatment of adults with relapsed or refractory cd22-positive b-cell precursor acute lymphoblastic leukaemia (all).

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

octapharma new zealand ltd - factor ii 220 [iu] - 760 [iu]; factor ix 500 [iu]; factor vii 180 [iu] - 480 [iu]; factor x 360 [iu] - 600 [iu]; plasma protein fraction 260mg - 820mg; protein c 140 [iu] - 620 [iu]; protein s precursor 140 [iu] - 640 [iu] - injection with diluent - 500 iu - active: factor ii 220 [iu] - 760 [iu] factor ix 500 [iu] factor vii 180 [iu] - 480 [iu] factor x 360 [iu] - 600 [iu] plasma protein fraction 260mg - 820mg protein c 140 [iu] - 620 [iu] protein s precursor 140 [iu] - 640 [iu] excipient: heparin sodium polysorbate 80 sodium citrate tributyl phosphate water for injection - · treatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required. · treatment of bleeding and perioperative prophylaxis in congenital deficiency of any of the vitamin k dependent coagulation factors when purified specific coagulation factor product is not available.

Singapura - Inggeris - HSA (Health Sciences Authority)

qt instruments (s) pte ltd - yttrium (90) chloride - solution - 1850 mbq at calibration time and date - yttrium (90) chloride 1850 mbq at calibration time and date

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - factor ii 800 [iu] - 1920 [iu]; factor ix 800 [iu] - 1240 [iu]; factor vii 400 [iu] - 1000 [iu]; factor x 880 [iu] - 2400 [iu]; protein c 600 [iu] - 1800 [iu]; protein s precursor 480 [iu] - 1520 [iu]; prothrombin complex concentrates 240mg - 560mg (includes clotting factors, protein c & protein s) - powder for injection with diluent - 1000 iu - active: factor ii 800 [iu] - 1920 [iu] factor ix 800 [iu] - 1240 [iu] factor vii 400 [iu] - 1000 [iu] factor x 880 [iu] - 2400 [iu] protein c 600 [iu] - 1800 [iu] protein s precursor 480 [iu] - 1520 [iu] prothrombin complex concentrates 240mg - 560mg (includes clotting factors, protein c & protein s) excipient: albumin antithrombin iii heparin hydrochloric acid sodium chloride sodium citrate sodium hydroxide water for injection - treatment and perioperative prophylaxis of bleeding in acquired deficiency of prothrombin complex factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.